Forest acquisition whets M&A appetite

Actavis's Forest acquisition has piqued industry interest in Teva Pharmaceutical. Bloomberg reports that the Maxim Group thinks that the Actavis move has boosted “prospects that Teva could be acquired next.” Among Maxim's reasons: a new CEO, a shrinking executive board, and a cost-cutting strategy.

Teva would not comment on Bloomberg's story.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.